

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				Complete if Known	
				Application Number	08/737,446
				Filing Date	November 14, 1996
				First Named Inventor	Dupre
				Group Art Unit	1644
				Examiner Name	P.J. Nolan
Sheet		of	2	Attorney Docket Number	030639.0034.CPA1

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MMDDYYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
PN	AA	5,424,286		Eng	6/13/95	

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
PN	AB	EP	0044168		Lundt	01-20-82		
	AC	EP	708179A3		Chen	04-24-96		
	AD	WO	90/11296		Habener	03-20-89		
	AE	WO	91/11457		Buckley	08-08-91		
	AF	WO	93/18786		Efendic	09-30-93		
	AG	WO	93/25579		Pfizer, Inc.	12-23-93		
	AH	WO	93/18786		Efendic, S.	9-30-93		

Examiner Signature	<i>Patrick J. Nolan</i>	Date Considered	7/26/01
-----------------------	-------------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	08/737,446		
		Filing Date	November 14, 1996		
		First Named Inventor	Dupre		
		Group Art Unit	1644		
		Examiner Name	P.J. Nolan		
Sheet		of	2	Attorney Docket Number	030639.0034.CPA1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
PN	AI	ANDREWS, et al, "Isolation and structures of Glucagon and Glucagon-like peptide from catfish pancreas," <u>Journal of Biological Chemistry</u> 260:3910-3914 (1985)		
	AJ	BELL, et al, "Hamster preproglucagon contains the sequence of glucagon and two related peptides," <u>Nature</u> 302:716-718 (1983)		
	AK	D'ALESSIO, D.A., et al. "Glucagon-like Peptide 1 Enhances Glucose Tolerance Both by Stimulation of Insulin Release and by Increasing Insulin-independent Glucose Disposal," <u>J. Clin. Invest.</u> , 93:2263-2266 (1994)		
	AL	FALOONA, G.R., et al, in <u>Methods of Hormone Radioimmunoassay</u> , Unger, B.M. (eds), Academic Press, NY, pp 317-330 (1974)		
	AM	GHIGLIONE, et al, "How Glucagon-Like is Glucagon-Like peptide?" <u>Diabetologia</u> 27:599-600 (1984)		
	AN	GOTH, <u>Medical Pharmacology: Principles and Concepts</u> , Mosby Co., St. Louis, pp. 19-20 (1984)		
	AO	GUTNIAK, M., et al, "Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus," <u>New England Journal of Medicine</u> 326(20):1316-1322 (1992)		
	AP	KREYMANN, B., et al, "Glucagon-like peptide-1 7-36: A physiological incretin in man," <u>Lancet</u> 2:1300-1304 (1987)		
	AQ	KUMAR, V., et al, "Amino acid variations at a single residue in an autoimmune peptide profoundly affect its properties: T-cell activation, major histocompatibility complex binding, and ability to block experimental allergic encephalomyelitis," <u>Proc. Natl. Acad. Sci.</u> 87:1337-1341 (1990)		
	AR	NATHAN, D.M., et al, "Insulinotropic Action of Glucagonlike Peptide-1-(7-37) in Diabetic and Nondiabetic Subjects," <u>Diabetes Care</u> 15:270-276 (1992)		
	AS	NGO, J.T., in <u>The Protein Folding Problem and Tertiary Structure Prediction</u> , Merz (ed), Birkhauser Boston, pp 492-495 (1992)		
	AT	SCHMIDT, et al, "Glucagon-Like peptide-1 but not Glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets," <u>Diabetologia</u> 28:704-707 (1985)		
	AU	UTTENTHAL, et al, "Molecular forms of Glucagon-like peptide-1 in human pancreas and Glucagonomas," <u>The Journal of Clinical Endocrinology and Metabolism</u> 61:472-479 (1985)		
	AV	WETTERGREN, et al, "Truncated GLP-1 (Proglucagon 78-107-Amide) inhibits gastric and pancreatic functions in man," <u>Dig Dis Sci</u> 38:665-673 (1993)		
Examiner Signature			Date Considered	7/26/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.